NCT01964235 - Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

INC280

INC280 will be administered orally and continuously on a twice a day dosing schedule.

DRUG

Placebo

Placebo will be administered orally and continuously on a twice a day dosing schedule.

Trial Locations (15)

Novartis Investigative Site, Geneva

Novartis Investigative Site, Kogarah

Novartis Investigative Site, Bern

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Córdoba

Novartis Investigative Site, Montpellier

Novartis Investigative Site, Essen

Novartis Investigative Site, Lille

Research Medical Center Onc Dept, Kansas City

Novartis Investigative Site, Clichy

Novartis Investigative Site, Würzburg

Massachusetts General Hospital Mass General Hospital, Boston

Novartis Investigative Site, Nice

Novartis Investigative Site, Hong Kong

Novartis Investigative Site, Hong Kong SAR